Literature DB >> 22649144

Targeting the B-cell lymphoma/leukemia 2 family in cancer.

Matthew S Davids1, Anthony Letai.   

Abstract

The B-cell lymphoma/leukemia 2 (BCL-2) family of proteins has attracted the attention of cancer biologists since the cloning of BCL-2 more than 25 years ago. In the intervening decades, the way the BCL-2 family controls commitment to programmed cell death has been greatly elucidated. Several drugs directed at inhibiting BCL-2 and related antiapoptotic proteins have been tested clinically, with some showing considerable promise, particularly in lymphoid malignancies. A better understanding of the BCL-2 family has also provided insight into how conventional chemotherapy selectively kills cancer cells and why some cancers are more chemosensitive than others. Further exploitation of our understanding of the BCL-2 family promises to offer improved predictive biomarkers for oncologists and improved therapies for patients with cancer.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22649144      PMCID： PMC4979238          DOI： 10.1200/JCO.2011.37.0981

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  69 in total

1.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

2.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Authors:  Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Authors:  Mai Nguyen; Richard C Marcellus; Anne Roulston; Mark Watson; Lucile Serfass; S R Murthy Madiraju; Daniel Goulet; Jean Viallet; Laurent Bélec; Xavier Billot; Stephane Acoca; Enrico Purisima; Adrian Wiegmans; Leonie Cluse; Ricky W Johnstone; Pierre Beauparlant; Gordon C Shore
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

4.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

Authors:  Jing Deng; Nicole Carlson; Kunihiko Takeyama; Paola Dal Cin; Margaret Shipp; Anthony Letai
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

5.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

6.  Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane.

Authors:  Tomomi Kuwana; Mason R Mackey; Guy Perkins; Mark H Ellisman; Martin Latterich; Roger Schneiter; Douglas R Green; Donald D Newmeyer
Journal:  Cell       Date:  2002-11-01       Impact factor: 41.582

7.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

Authors:  E H Cheng; M C Wei; S Weiler; R A Flavell; T W Mak; T Lindsten; S J Korsmeyer
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

8.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues.

Authors:  T Lindsten; A J Ross; A King; W X Zong; J C Rathmell; H A Shiels; E Ulrich; K G Waymire; P Mahar; K Frauwirth; Y Chen; M Wei; V M Eng; D M Adelman; M C Simon; A Ma; J A Golden; G Evan; S J Korsmeyer; G R MacGregor; C B Thompson
Journal:  Mol Cell       Date:  2000-12       Impact factor: 17.970

9.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

10.  Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation.

Authors:  Y Tsujimoto; E Jaffe; J Cossman; J Gorham; P C Nowell; C M Croce
Journal:  Nature       Date:  1985 May 23-29       Impact factor: 49.962
View more
  110 in total

1.  Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.

Authors:  Kazuyuki Murase; Haesook T Kim; O R Gregory Bascug; Yutaka Kawano; Jeremy Ryan; Ken-ichi Matsuoka; Matthew S Davids; John Koreth; Vincent T Ho; Corey Cutler; Philippe Armand; Edwin P Alyea; Bruce R Blazar; Joseph H Antin; Robert J Soiffer; Anthony Letai; Jerome Ritz
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

2.  Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

Authors:  Rongqing Pan; Vivian R Ruvolo; Jun Wei; Marina Konopleva; John C Reed; Maurizio Pellecchia; Michael Andreeff; Peter P Ruvolo
Journal:  Blood       Date:  2015-06-04       Impact factor: 22.113

3.  Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

Authors:  Xiaojia Niu; Jianyun Zhao; Jun Ma; Chengzhi Xie; Holly Edwards; Guan Wang; J Timothy Caldwell; Shengyan Xiang; Xiaohong Zhang; Roland Chu; Zhihong J Wang; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

4.  Cancer therapeutics: Pulling the plug on BCL-X(L).

Authors:  Paul S Jeng; Emily H Cheng
Journal:  Nat Chem Biol       Date:  2013-06       Impact factor: 15.040

Review 5.  Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?

Authors:  Heinrich J Huber; Ross G McKiernan; Jochen H M Prehn
Journal:  J Mol Med (Berl)       Date:  2014-01-30       Impact factor: 4.599

Review 6.  Self-consumption: the interplay of autophagy and apoptosis.

Authors:  Guillermo Mariño; Mireia Niso-Santano; Eric H Baehrecke; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01-08       Impact factor: 94.444

Review 7.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

Review 8.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

9.  Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.

Authors:  Timothy G Whitsett; Ian T Mathews; Michael H Cardone; Ryan J Lena; William E Pierceall; Michael Bittner; Chao Sima; Janine LoBello; Glen J Weiss; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2014-01-27       Impact factor: 5.852

Review 10.  Progress against follicular lymphoma.

Authors:  Jonathan H Schatz; Elisa Oricchio; Soham D Puvvada; H Guido Wendel
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.